Showing 118 of 118on this page. Filters & sort apply to loaded results; URL updates for sharing.118 of 118 on this page
Janux Therapeutics And Bristol Myers Squibb Sign Up To $850 Million ...
Janux Therapeutics - 22 Fillmore
Janux Therapeutics Announces Positive Interim Clinical Data from Phase ...
Janux | T Cell Immuno-oncology | Technology Platform
Janux Therapeutics | Novel T Cell Immunotherapies
Janux研发日：全面布局前抗体实体瘤TCE Armstrong 2025年7月24日， Janux Therapeutics 举办研发日活动 ...
Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy ...
Bristol Myers Squibb and Janux Launch Partnership on Tumor-Activated T ...
Janux Therapeutics | T Cell Immunotherapy | Clinical Trials | Sara Walsh
Janux | T Cell Immuno-oncology | PSMA-TRACTr (JANX007)
BMS aprovecha la plataforma de Janux para desarrollar una terapia ...
JANX007 / Janux Therapeutics
Janux Therapeutics | Tumor-activated T Cell Immunotherapy
Janux Therapeutics Plummets 49%: What's Behind the Biotech's Sharp Slide?
Bristol Myers Squibb Partners with Janux Therapeutics for $850M T Cell ...
Janux Therapeutics (JANX) | IPO 2021
Janux | T Cell Immuno-oncology | PSMA-TRACTr (JANX007) | Janux Therapeutics
Janux | T Cell Immunotherapy for Cancer & Autoimmune Disease
Janux Therapeutics: Clinical Momentum and Strategic Expansion Position ...
Janux Soars On Early Efficacy, Safety For ‘Masked’ T-Cell Engagers
PSMA-TRACTr (JANX014) - Janux Therapeutics
Janux Therapeutics | T Cell Immunotherapy | Job Openings
Janux axes solid tumor T-cell engager after poor ph. 1 showing
Bristol Myers signs deal with Janux on T cell engager for $50M upfront
#tractr #tracir #tcellengagers #cancer #oncology #immunotherapy | Janux ...
Janux Therapeutics: What's My Inflection Point? (NASDAQ:JANX) | Seeking ...
Janux Therapeutics on LinkedIn: #tractr #tracir #tcellengagers #cancer ...
Janux Stock: A High-Risk/High-Reward Bet On Oncology And Autoimmune ...
Buy Janux Therapeutics stock | $JANX Share Price | Lightyear
Janux Therapeutics Stock Craters After ‘Positive’ Cancer Data. Why It’s ...
BMS vuelve a intentarlo con activadores de células T y recurre a Janux ...
Janux Therapeutics: Insider Spending Reflects Confidence in Biotech's ...
Janux lets the genie out of the bottle | ApexOnco - Clinical Trials ...
Janux股价翻倍：PSMA/CD3双抗初步临床获得积极数据 Armstrong 2024年2月26日， Janux Therapeutics ...
Janux hires CMO after T cell engager deal with Bristol Myers; A batch ...
Janux Therapeutics Interim Clinical Data For JANX007 in mCRPC - YouTube
Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose ...
Merck cuts $1bn deal with Janux for cancer T-cell therapies | pharmaphorum
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study ...
Janux Therapeutics Enters $850 Million Collaboration and Exclusive ...
Janux Therapeutics Announces First Patient Dosed with JANX008 in First ...
Home - Janux Therapeutics - Immunotherapies for Cancer
Janux大涨67%：PSMA/CD3前抗体取得突破疗效 Armstrong 2024年12月2日， Janux Therapeutics ...
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical ...
Janux Therapeutics presents preclinical data at the 18th Annual PEGS ...
Breaking: $850 Million Deal between Janux and BMS for Cancer Therapy ...
Medtech Alert on LinkedIn: Janux Therapeutics Announces First Patient ...
Janux Therapeutics Launches Massive $300M Public Offering to Fuel ...
Trophoblast antigen 2 tumour activated T-cell engager therapy (Janux ...
April 21 2023
#mcrpc #janx #tcellengagers #cancer #oncology #immunotherapy # ...
Merck Strikes $1B+ Deal to Leverage Janux's T Cell Engager Program ...
Janux：戴上“mask”的双抗 2580字19图，阅读大约需要8分钟。文章首发于丰硕创投，欢迎朋友圈与微信转发。公众号及其它平台转载请后台 ...
(Prostate specific membrane antigen tumour activated T-cell engager ...
Prostate specific membrane antigen tumour activated T-cell engager ...
BMS Commits $850M to Tumor-Activated T-Cell Engagers; Corxel Raises ...
JANX Stock Edges Up After Hours After Discontinuing Cancer Program In ...
Janux's shares jump 130% as analysts see blockbuster potential in phase ...
BMS taps into Janux's platform to develop tumour-activated therapeutic
【即時新聞】Janux攜手BMS簽署8.5億美元抗癌藥開發合約激勵盤前股價大漲逾12% | CMoney投資網誌
.jpg){kind=logo}
%203.jpg)
.jpg){kind=logo}
